Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Eli Lilly and Company (Lilly) to accelerate biologics discovery using artificial intelligence.
Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery
Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules, today announced its $130 million Series B financing round co-led by Oak HC/FT and General Catalyst. This round of financing values the company at $1.3 billion.
Chai Discovery Announces $70 million Series A To Transform Molecular Design
Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round.
Chai Discovery Unveils Chai-2 Breakthrough, Achieving Fully De Novo Antibody Design With AI
Chai Discovery, which builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, today announced a breakthrough in the de novo design of antibodies. The company’s latest model, Chai-2, demonstrates a remarkable antibody design hit rate close to 20%. Prompted with just the target and epitope, Chai-2 successfully designs all complementarity-determining regions (CDRs) entirely from scratch—a breakthrough in a field where traditional techniques, including those based on AI, consistently show hit rates below 0.1%.
